Patent intelligence · US
US 8697744
Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors
Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors
Patent details — US 8697744
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 15, 2014
- Expiration
- Apr 10, 2034
- Applicant
- Addex Pharma, S.A.
- Claims
- 12
- CPC classes
- A61K, A61K31/137, A61K31/277, A61K31/429
Quick answer
US 8697744 (Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors) is held by Addex Pharma, S.A.. Status: granted. Granted Apr 15, 2014. Expires Apr 10, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Addex Pharma, S.A.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/137, A61K31/277, A61K31/429, A61K45/06, A61K9/0048
More from Addex Pharma, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 11071729
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted -
US 10071095
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
granted -
US 9938270
Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
granted -
US 9765091
Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
granted -
US 9737533
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9266834
1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
granted -
US 9226930
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9132122
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted
Frequently asked questions
What is US patent 8697744?
US 8697744 (Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors) is held by Addex Pharma, S.A.. Status: granted. Granted Apr 15, 2014. Expires Apr 10, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8697744?
Addex Pharma, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 8697744 expire?
Our index shows an expiration date of Apr 10, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.